Proof-of-Concept Study Signals AX-8’s Potential in Chronic Cough Treatment, Especially in Patients with Moderate-to-Severe Throat Discomfort
Read more
Latest News
Proof-of-Concept Study Signals AX-8’s Potential in Chronic Cough Treatment, Especially in Patients with Moderate-to-Severe Throat Discomfort
Read moreAX-8 reduces cough frequency and improves patient-reported outcomes in patients with chronic cough
Read moreTRPM8 Pathway May Play Antitussive and Counterirritant Role in Chronic Cough; Data Expected Mid 2022
Read moreAxalbion will soon start recruitment for a Phase 2 study to assess the efficacy and safety of AX-8 in patients with chronic cough.
Read moreAxalbion therapeutics Limited, Axalbion SA's parent company, has been incorporated in UK, 24 February 2021.
Read moreDr. Kitt joined Axalbion as Chief Executive Officer in November 2019, bringing more than 30 years of clinical development experience and industry expertise.
Read moreResults of the AX8-001 study (EudraCT no. 2017-003108-27) titled "A PILOT STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF AX-8 FOR THE TREATMENT OF REFRACTORY CHRONIC COUGH" are available on EU Clinical Trials Register:
Read moreIf you need further information please feel free to contact us.
Read more